Dr. Peter Sheehan Joins Regenesis Biomedical as Director and Advisor

Dr. Peter Sheehan Joins Regenesis Biomedical as Director and Advisor 

Diabetes and wound healing expert strengthens clinical research program

SCOTTSDALE, Ariz., March 2 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical technology company focused on regenerative medicine, announced today that Peter Sheehan, MD, has joined the company's Board of Directors and will serve as Chairman of their Medical Advisory Board.
 

Dr. Sheehan is an internationally respected specialist in the field of diabetes. Areas of clinical and research interest for Dr. Sheehan include peripheral artery disease, diabetic neuropathy, and wound healing. He has served as the American Diabetes Association (ADA) Foot Council Chairman, on the national Board of Directors, and currently as Chairman of the Cardiometabolic Risk Initiative. Dr. Sheehan was on the Board of Directors of the Wound Healing Society and served as President of the Wound Healing Foundation. He is also a member of the Steering Committee of the P.A.D. Coalition (peripheral artery disease). He is a graduate of the SUNY-Downstate School of Medicine, where he also completed his residency in Internal Medicine. Dr. Sheehan continued his training at the Yale University School of Medicine in New Haven where he completed a fellowship in Endocrinology and Metabolism.
 

"On behalf of the entire company, we welcome Peter to the Board of Directors of Regenesis, and his position as Chairman of our Medical Advisory Board," said John Voris, Chairman of the Board of Directors of Regenesis Biomedical. "His clinical experience, expertise, and standing within the medical community will dramatically help us direct our clinical research investments."
 

Dr. Sheehan commented, "Regenesis Biomedical has demonstrated commitment to advancing the clinical and scientific knowledge in the field of tissue regeneration. The Provant Therapy System has treated over 5,000 patients, and, through new clinical trials, we hope to enable further access to patients in need."
 

About the Provant Therapy System
 

Provant uses pulsed radio frequency energy (PRFE) to facilitate reduction of the pain and edema associated with post-operative, superficial soft tissues.
 

About Regenesis Biomedical
 

Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. Regenesis developed, patented, and now markets the Provant Therapy System. Our customers include health care facilities, acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics.
 


  Contact: Regenesis Biomedical, Inc.
  Scott Robey, Vice President Marketing
  www.regenesisbio.com
  480-970-4970 phone


  Regenesis, the Regenesis logo, and Provant are registered trademarks of
  Regenesis Biomedical, Inc., Scottsdale AZ 85257. The Provant yellow is a
        trademark of Regenesis Biomedical, Inc., Scottsdale AZ 85257.

Source: Regenesis Biomedical, Inc.

CONTACT: Scott Robey, Vice President Marketing of Regenesis Biomedical,
Inc., +1-480-970-4970
 

Web Site: http://www.regenesisbio.com/

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.